0003-2187 : Orencia 250 mg/15ml Intravenous Injection, Powder, Lyophilized, for Solution


NDC: 0003-2187
Labeler: E.r. Squibb & Sons, L.L.C.
Product Type: Human Prescription Drug
Drug Name:  Orencia
Dosage Form: Intravenous Injection, Powder, Lyophilized, for Solution
Application #: BLA125118
Rev. Date: 


NDC Package Codes:

  • 0003-2187-10: 1 VIAL, SINGLE‑USE IN 1 CELLO PACK (0003‑2187‑10) > 15 ML IN 1 VIAL, SINGLE‑USE
  • 0003-2187-13: 1 VIAL, SINGLE‑USE IN 1 CARTON (0003‑2187‑13) > 15 ML IN 1 VIAL, SINGLE‑USE

Active Ingredients:

  • Abatacept

Dosage Strength:

  • 250 mg/15mL

Pharmaceutical Classes:

  • Decreased Cytokine Activity [PE]
  • Selective T Cell Costimulation Modulator [EPC]
  • Recombinant Fusion Proteins [CS]

Related Products:

Based on records with the same trade name.
  • 0003-2188 Orencia 125 mg/ml Subcutaneous Injection, Solution by E.r. Squibb & Sons, L.L.C.
  • 0003-2814 Orencia 50 mg/.4ml Subcutaneous Injection, Solution by E.r. Squibb & Sons, L.L.C.
  • 0003-2818 Orencia 87.5 mg/.7ml Subcutaneous Injection, Solution by E.r. Squibb & Sons, L.L.C.

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0003-2187 QR Code

< Prev: 0003-1968Next: 0003-2188 >

Related Discussions:

Giant Cell Arteritis/Abatacept Study
We are interested in finding out whether abatacept has been successful in treating Giant Cell Arteritis, before joining ...
Orencia Side Effects
Can Orencia possibly cause chest pain and shortness of breath? ## It sounds like you may be having an allergic reaction ... 2 replies




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.